Clinical Trials

Clinical Trial 1
Clinical Trial 1

Sites and Investigators

Kuala Lumpur Hospital (HKL) — Dr Noor Zalifah Binti Zakaria
National Cancer Institute (IKN) — Dr Wong Yoke Fui, Florence
Sarawak General Hospital — Dr Yusra Binti Hadi
Sultan Ismail Hospital, Johor Bahru — Dr Kumutha A/P Chalaya
University Malaya Medical Centre (UMMC) — Dr Wan Zamaniah Binti Wan Ishak @ Wan Mohammad

Key Criteria of the Study

Aged 18 or older
Histologically confirmed diagnosis of epithelial high-grade ovarian, fallopian tube, or primary peritoneal carcinoma, per local assessment.
Newsly diagnosed FIGO Stage 3 or 4.
HER2 expression per 2016 ASCO-CAP gastric cancer IHC scoring (3+/2+/1+) guidelines by prospective central testing.

Clinicaltrials.gov Identifier

NCT06819007

NMRR ID

NMRRID-25-00674-MT8

Further details

DESTINY-Ovarian01_NCSM

Registration

Email: patient.recruitment@clinicalresearch.my

Contact Number: +603 7932 2275 (207)/(208)

Clinical Trial 2
Clinical Trial 2

Sites and Investigators

Kuala Lumpur Hospital (HKL) – Dr Eznal Izwadi Bin Mohd Mahidin
National Cancer Institute (IKN) – Dr Suhana Binti Yusak
Raja Perempuan Zainab II Hospital, Kota Bharu – Dr Azza Binti Omar

Title

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)

Key Criteria of the Study

Stage IV metastatic NSCLC
Negative EGFR, ALK, ROS1
Tumor PD-L1 expression of tumor cell ≥ 50% (all participants must have an acceptable tumor sample available for central testing)

Clinicaltrials.gov Identifier

NCT06868277

NMRR ID

NMRRID-25-01183-NDT

Further details

Click Here
Clinical Trial 2
Clinical Trial 2

Sites and Investigators

Hospital Wanita dan Kanak-Kanak Sabah – Dr Cheo Seng Wee
Kuala Lumpur Hospital (HKL) – Dr Muthukkumaran A/L Thiagarajan
National Cancer Institute (IKN) – Dr Wong Yoke Fui, Florence
Sarawak General Hospital – Dr Voon Pei Jye

Title

A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-C477 in Patients with Selected Advanced Solid Tumors

Key Criteria of the Study

Indication: NSCLC (Non-Small Cell Lung Cancer)
    • Priority enrollment in 1L (first-line) patients
    • Also recruiting 2L+ (second line and beyond) patients
Biomarker Requirement: High CEA expression
    • IHC 2+/3+
    • Tumor Cells (TC) ≥ 50%

Clinicaltrials.gov Identifier

NCT06596473

NMRR ID

NMRRID-26-00009-API

Further details

Click Here

Registration

Email: patient.recruitment@clinicalresearch.my

Contact Number: +603 7932 2275 (207)/(208)

To find out more on how we can help,
+63-2698 7300 | contact@cancer.org.my

Back To Top